AstraZeneca
Immunai, AstraZeneca collaborate to optimize cancer clinical trials
Under the terms of the agreement, AstraZeneca will leverage Immunai’s platform and machine learning capabilities to inform certain oncology clinical trials.
US to move COVID-19 vaccines, treatments to private markets in 2023
AION, aMoon up for top scientific innovation award
COVID-19 booster shots are crucial, according to a Yale study
COVID-19: Blood cancer patients gain antibodies from vaccine booster - study
Blood cancer patients, already at high risk, often did not develop antibodies against COVID-19 from the first shot. But the booster and antibody therapy can provide a better shield.
Eight Israeli start-ups to form international collaborations
Following BetterPlayBio’s program, C2i Genomic, Nucle.ai, Medial Earlysign, iBex, Octopus, Imagene, Itamar Medical and iCardio are ready to hit the global market.
COVID-19: Israel approves AstraZeneca's Evusheld vaccine for immunocompromised
Evusheld has proven to be 83% effective in preventing serious illness and death from COVID-19.
AstraZeneca: Trial shows booster generates more protection from Omicron
AstraZeneca has developed the vaccine with researchers from Oxford University.
2021 was the year of the coronavirus vaccine
“I think we are in a revolution that no one believed would happen.”
AstraZeneca vaccine booster shot effective against Omicron - Oxford lab study
An Oxford University lab study yet to be peer-reviewed found that three AstraZeneca vaccines provide protection against the COVID Omicron variant.
GOP Rep. Marjorie Taylor Green owns stock in 3 COVID-19 vaccine makers
The congresswoman owns stock in Pfizer, AstraZeneca and Johnson&Johnson despite claiming to be unvaccinated and being among the most vocal opponents of vaccine mandates.
Next pandemic could be more lethal than COVID - AstraZeneca vaccine maker
The novel coronavirus has killed 5.26 million people across the world, wiped out trillions of dollars in economic output and turned life upside down for billions of people.
AstraZeneca's antibody cocktail helps prevent COVID-19 for at least 6 months
The data give hope of additional protection for people who do not respond well to vaccines, such as cancer patients.
AstraZeneca COVID-19 antibody drug offers 83% protection over six months
The Anglo-Swedish company also said that patients with mild-to-moderate COVID-19 showed a higher dose of the drug cut the risk of symptoms worsening by 88% when given within three days.
'Our COVID vaccine as good or better than AstraZeneca's' - Valneva
A study showed that Valneva's vaccine, given in two shots 28 days apart, prompted significantly fewer adverse reactions, such as arm pain and fever.
